<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16050</article-id><article-id pub-id-type="doi">10.25208/vdv16050</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience with the fixed combination of benzoyl peroxide and clindamycin in acne therapy</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт применения фиксированной комбинации бензоила пероксида и клиндамицина в терапии акне</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3360-2046</contrib-id><name-alternatives><name xml:lang="en"><surname>Verchoumova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Верхоумова</surname><given-names>Анна Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Resident</p></bio><bio xml:lang="ru"><p>ординатор</p></bio><email>anna.chernyshova2307@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0387-5481</contrib-id><name-alternatives><name xml:lang="en"><surname>Khairutdinov</surname><given-names>Vladislav R.</given-names></name><name xml:lang="ru"><surname>Хайрутдинов</surname><given-names>Владислав Ринатович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Assistant Professor</p></bio><bio xml:lang="ru"><p>д.м.н., доцент</p></bio><email>haric03@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7544-654X</contrib-id><name-alternatives><name xml:lang="en"><surname>Telichko</surname><given-names>Igor N.</given-names></name><name xml:lang="ru"><surname>Теличко</surname><given-names>Игорь Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>itelichko@yandex.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">S.M. Kirov Military Medical Academy</institution></aff><aff><institution xml:lang="ru">Военно-медицинская академия им. С.М. Кирова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Institute of Medical Education at the V.A. Almazov Scientific Research Centre</institution></aff><aff><institution xml:lang="ru">Институт медицинского образования Национального медицинского исследовательского центра им. В.А. Алмазова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Dermatovenerological Dispensary No. 4</institution></aff><aff><institution xml:lang="ru">Кожно-венерологический диспансер № 4</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-02-09" publication-format="electronic"><day>09</day><month>02</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-03-18" publication-format="electronic"><day>18</day><month>03</month><year>2024</year></pub-date><volume>100</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>56</fpage><lpage>62</lpage><history><date date-type="received" iso-8601-date="2023-10-03"><day>03</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-01-30"><day>30</day><month>01</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Verchoumova A.A., Khairutdinov V.R., Telichko I.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Верхоумова А.А., Хайрутдинов В.Р., Теличко И.Н.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Verchoumova A.A., Khairutdinov V.R., Telichko I.N.</copyright-holder><copyright-holder xml:lang="ru">Верхоумова А.А., Хайрутдинов В.Р., Теличко И.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/16050">https://vestnikdv.ru/jour/article/view/16050</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Acne is one of the most common dermatoses, affecting more than 9% of the world’s population. Acne negatively affects the patient’s quality of life and self-esteem, often leading to the development of anxiety and depression. The combination of pharmacological drugs with different mechanisms of action in one external dosage form can provide higher therapeutic efficacy.</p> <p><bold>Aims</bold>. To evaluate the effectiveness and tolerability of a combination drug with a fixed dose of clindamycin 1% and benzoyl peroxide 5% in the treatment of patients with mild to moderate papulopustular acne.</p> <p><bold>Methods</bold>. A single-center, open-label, observational, prospective study lasting 6 weeks was performed, which included 40 patients with mild to moderate papulopustular acne who received a gel with a fixed dose of clindamycin 1% and benzoyl peroxide 5% once a day. A clinical assessment of the effectiveness of therapy was carried out, PH, greasiness and moisture of the facial skin were measured, and the dynamics of the dermatological quality of life index was studied.</p> <p><bold>Results</bold>. The proportion of patients who showed significant improvement at the end of 6 weeks of treatment was 32/40 (80%). The total proportion of patients who showed significant and moderate improvement at the end of therapy reached 36/40 (90%).</p> <p><bold>Conclusion</bold>. The results obtained showed the high therapeutic effectiveness of the gel with a fixed dose of clindamycin 1% and benzoyl peroxide 5% in the treatment of mild to moderate papulopustular acne.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Акне — один из наиболее распространенных дерматозов, которым страдает более 9% населения всего мира. Акне негативно влияют на качество жизни и самооценку пациента, часто приводят к развитию тревожно-депрессивных состояний. Комбинация фармакологических препаратов с разным механизмом действия в одной наружной лекарственной форме может обеспечить более высокую терапевтическую эффективность.</p> <p><bold>Цель исследования.</bold> Оценка эффективности и переносимости комбинированного препарата с фиксированной дозой клиндамицина 1% и бензоила пероксида 5% в терапии пациентов с папуло-пустулезными акне легкой и средней степени тяжести.</p> <p><bold>Методы.</bold> Выполнено одноцентровое, открытое, наблюдательное, проспективное исследование продолжительностью 6 недель, в которое было включено 40 пациентов с папуло-пустулезными акне легкой и среднетяжелой степени, получавших гель с фиксированной дозой клиндамицина 1% и бензоила пероксида 5% 1 раз/сут. Проводилась клиническая оценка эффективности терапии, измерение рН, сальности и влажности кожи лица, изучалась динамика дерматологического индекса качества жизни.</p> <p><bold>Результаты. </bold>Доля больных, у которых наблюдалось значительное улучшение к концу 6-й недели лечения, составила 32/40 (80%). Суммарная доля пациентов, у которых к окончанию терапии отмечалось значительное и умеренное улучшение, достигла 36/40 (90%).</p> <p><bold>Заключение. </bold>Полученные результаты показали высокую терапевтическую эффективность геля с фиксированной дозой клиндамицина 1% и бензоила пероксида 5% в лечении папуло-пустулезной формы акне легкой и среднетяжелой степени.</p></trans-abstract><kwd-group xml:lang="en"><kwd>papulopustular acne</kwd><kwd>benzoyl peroxide</kwd><kwd>clindamycin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>папуло-пустулезные акне</kwd><kwd>бензоила пероксид</kwd><kwd>клиндамицин</kwd></kwd-group><funding-group><funding-statement xml:lang="en">S.M. Kirov Military Medical Academy; The Institute of Medical Education at the V.A. Almazov Scientific Research Centre; Dermatovenerological Dispensary No. 4</funding-statement><funding-statement xml:lang="ru">Военно-медицинская академия им. С.М. Кирова; Институт медицинского образования Национального медицинского исследовательского центра им. В.А. Алмазова; Кожно-венерологический диспансер № 4</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Eichenfield DZ, Sprague J, Eichenfield LF. Management of Acne Vulgaris: A Review. JAMA. 2021;326(20):2055–2067. doi: 10.1001/jama.2021.17633</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Самцов А.В., Аравийская Е.Р. Акне и розацеа: монография. М.: Фармтек; 2021. 400 c. [Samtsov AV, Araviiskaya EA. Akne i rozacea. Monografiya (Acne and rosacea. Мonography). Moscow: Farmtec; 2021. 400 p. (In Russ.)]</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e33. doi: 10.1016/j.jaad.2015.12.037</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(Suppl 5):1–7. doi: 10.1111/jdv.13186</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hazarika N. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. J Dermatolog Treat. 2021;32(3):277–285. doi: 10.1080/09546634.2019.1654075</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dreno B, Pecastaings S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl 2):5–14. doi: 10.1111/jdv.15043</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996;106(1):176–182. doi: 10.1111/1523-1747.ep12329907</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol. 2005;153(6):1105–1113. doi: 10.1111/j.1365-2133.2005.06933.x</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Melnik BC. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. Clin Cosmet Investig Dermatol. 2015;8:371–388. doi: 10.2147/CCID.S69135</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tan JKL, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12. doi: 10.1111/bjd.13462</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001;67(2):165–169.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Green L, Cirigliano M, Gwazdauskas JA, Gonzalez P. The Tolerability Profile of Clindamycin 1%/Benzoyl Peroxide 5% Gel vs. Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel for Facial Acne: Results of Two Randomized, Single-Blind, Split-Face Studies. J Clin Aesthet Dermatol. 2012;5(5):16–24.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Thiboutot DM, Dreno B, Abanmi A, Alexis AF, Araviiskaia E, Cabal MIB, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1–S23.e1. doi: 10.1016/j.jaad.2017.09.078</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Аравийская Е.Р., Самцов А.В., Соколовский Е.В., Бакулев А.Л., Мурашкин Н.Н., Карамова А.Э. К вопросу об оценке по степени тяжести и классификации акне. Вестник дерматологии и венерологии. 2022;98(6):48–54. [Araviiskaya ER, Samtsov AV, Sokolovsky EV, Bakulev AL, Murashkin NN, Karamova AE. Revisiting the question of assessment by severity and classification of acne. Vestnik Dermatologii i Venerologii. 2022;98(6):48–54. (In Russ.)] doi: org/10.25208/vdv1374</mixed-citation></ref></ref-list></back></article>
